AGILENT TECHNOLOGIES, INC. (A) Form 10-Q — Sep 1, 2026

$AForm 10-QFiled Sep 1, 2026, 4:11 PM ET0001090872-26-000064Original filing

Agilent Technologies reported Q3 fiscal 2026 net revenue of $1,878 million, up 8% year over year, with net income of $362 million and diluted EPS of $1.28 versus $1.18 a year earlier. Growth came from all three segments, all geographic regions, and most key end markets, led by Life Sciences and Diagnostics up 11%. For the first nine months of fiscal 2026, revenue reached $5,511 million (up 8%) with net income of $1,006 million ($3.55 diluted EPS), while operating cash flow improved to $1,064 million from $1,014 million in the prior-year period.

Key figures

Eps: $1.28 diluted (Q3); $3.55 diluted (nine months)
Revenue: $1,878 million (Q3 FY26); $5,511 million (nine months FY26)
Net Income: $362 million (Q3); $1,006 million (nine months)
Total Debt: $3,949 million ($304 million short-term + $3,645 million long-term)
Debt Amount: $600 million (2032 senior notes issued June 25, 2026 at 99.968% of principal)
Revenue Yoy: 8% (both Q3 and nine months)
Total Assets: $13,967 million
Cash Position: $1,758 million
Interest Rate: 4.90% fixed (2032 senior notes)
Maturity Date: January 15, 2032 (2032 senior notes)
Shares Outstanding: 281928854
Biocare Goodwill: $549 million
Segment Revenue Q3: Life Sciences & Diagnostics $746M (+11%), Agilent CrossLab $786M (+6%), Applied Markets $346M (+7%)
Effective Tax Rate Q3: 18.5% (vs 8.2% in Q3 FY25)
Senior Notes Fair Value: $3,749 million (carrying value $3,928 million)
Biocare Net Consideration: $950 million (acquired June 24, 2026)
Dividends Paid Nine Months: $216 million ($0.765 per share)
Share Repurchases Nine Months: $295 million (2.212 million shares)
Operating Cash Flow Nine Months: $1,064 million (vs $1,014 million prior year)
Fy25 Plan Expected Annual Savings: $90-95 million
Fy26 Plan Expected Annual Savings: $30-35 million
Remaining Buyback Authorization: $1,654 million under $2.0 billion 2024 repurchase program
Commercial Paper Program Capacity: $1.5 billion
Restructuring Expense Since Inception: $124 million across FY25 and FY26 plans

Price after filing

1 day: +1.0%7 days: -2.1%30 days: +14.9%

Close on the filing date to close N calendar days later (from $149.93). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.